Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R. Campos S, et al. Among authors: krasner c. Int J Clin Oncol. 2022 Dec;27(12):1881-1890. doi: 10.1007/s10147-022-02247-0. Epub 2022 Nov 8. Int J Clin Oncol. 2022. PMID: 36344654 Clinical Trial.
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
Penson RT, Seiden MV, Goodman A, Fuller AF Jr, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare. Penson RT, et al. Among authors: krasner c. Gynecol Oncol. 2004 Jun;93(3):702-7. doi: 10.1016/j.ygyno.2004.02.028. Gynecol Oncol. 2004. PMID: 15196868 Clinical Trial.
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.
Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare. Penson RT, et al. Among authors: krasner c. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41. doi: 10.1111/j.1525-1438.2005.00482.x. Int J Gynecol Cancer. 2005. PMID: 16343179 Free article. Clinical Trial.
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A; Gynecologic Cancer Program of Dana Farber-Harvard Cancer Center. Matulonis UA, et al. Among authors: krasner cn. Gynecol Oncol. 2006 Oct;103(1):160-4. doi: 10.1016/j.ygyno.2006.02.017. Epub 2006 Mar 29. Gynecol Oncol. 2006. PMID: 16566993 Clinical Trial.
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV; Dana-Farber/Partners CancerCare and Harvard Vanguard Medical Associates. Matulonis UA, et al. Among authors: krasner cn. Gynecol Oncol. 2006 Nov;103(2):575-80. doi: 10.1016/j.ygyno.2006.04.017. Epub 2006 Jun 23. Gynecol Oncol. 2006. PMID: 16806439 Clinical Trial.
65 results